Studies with Severe Methodological Issues Evaluating HCQ for COVID-19 Treatment.
Studies with Severe Methodological Issues Evaluating HCQ for COVID-19 Treatment.
Study Design | Pts | Study Groups | Results: Primary/Secondary* Outcomes | Methodological Issues |
---|---|---|---|---|
Comparative multinational registry analysis29 | 96,032 | 1. CQ
2. CQ+macrolide 3. HCQ 4. HCQ+macrolide 5. SOC |
Primary Outcome
|
|
Comparative observational study26 | 42 | 1. HCQ
2. SOC |
Sig.Dif. in virological cure rates between HCQ (70%) and SOC (12.5%) groups (P=0.001) |
|
Re-analysis of study,26 including the missing datasets27 | 42 | 1. HCQ
2. SOC |
No significant differences in virological cure rates on treatment days 3, 4, 5, or 6* | None. Study refers to methodological problems of the abovementioned study |
Uncontrolled observational study28 aimed at replicating the above comparative observational study26 | 11 | 1. HCQ | 20% of patients were virologically cured at day 5–6 post-inclusion* |